Cuál es el precio por Coeptis Therapeutics Holdings, Inc. (COEP)

Precio por Coeptis Therapeutics Holdings, Inc. (COEP) es de$4.81

Cuál es la capitalización de mercado por Coeptis Therapeutics Holdings, Inc. (COEP)

Capitalización de mercado por Coeptis Therapeutics Holdings, Inc. (COEP) es $29.01M

Ganancias de Coeptis Therapeutics Holdings, Inc. (COEP)

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company’s product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Año	Ganancias	Cambiar
Not enough data for the provided dates.

Año

Ganancias

Cambiar

Not enough data for the provided dates.

Empresa	Ganancias	Diferencia de ganancias	País
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Moderna, Inc. MRNA.US	$-3.09B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$1.61B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

Ganancias

Diferencia de ganancias

País